Bayer Group - Investor-Relations
Bayer Group - Investor-Relations
Bayer Group - Investor-Relations
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
80 COMBINED MANAGEMENT REPORT<br />
3. Business Development by Subgroup, Segment and Region<br />
3.4 Business Development by Region<br />
3.4 Business Development by Region<br />
Sales by Region and Segment (by Market)<br />
BAYER ANNUAL REPORT 2011<br />
3.5 Business Development in the Emerging Markets<br />
The emerging markets contributed signifi cantly to sales growth in 2011. For reporting purposes we<br />
have defi ned these markets as Asia (excluding Japan), Latin America, Eastern Europe, Africa and the<br />
Middle East.<br />
Sales in these emerging markets rose by 9.0% (Fx adj.) in 2011 to €13,290�million (2010: €12,493�million),<br />
with all regions contributing to the increase. The emerging markets accounted for 36.4% of<br />
sales (2010: 35.6%).<br />
Percentage Sales Breakdown by Industrialized Countries and Emerging Markets 2011<br />
(currency-adjusted changes in parentheses) [Graphic 3.17]<br />
63.6% (Fx adj. +3.7%)<br />
Industrialized countries<br />
Europe North America<br />
2010 2011 2010 2011<br />
Fx adj.<br />
Fx adj.<br />
€ million € million % yoy % yoy € million € million % yoy % yoy<br />
HealthCare 6,375 6,376 0.0 – 0.1 4,666 4,360 – 6.6 – 2.4<br />
Pharmaceuticals 3,784 3,658 – 3.3 – 3.5 2,382 2,048 – 14.0 – 10.5<br />
Consumer Health 2,591 2,718 + 4.9 + 4.8 2,284 2,312 + 1.2 + 6.0<br />
CropScience 2,381 2,505 + 5.2 + 5.7 1,535 1,703 + 10.9 + 14.3<br />
MaterialScience 3,950 4,413 + 11.7 + 11.8 2,022 2,109 + 4.3 + 9.6<br />
<strong>Group</strong> (incl. reconciliation) 13,751 14,441 + 5.0 + 5.0 8,228 8,177 – 0.6 + 3.6<br />
2010 fi gures restated<br />
yoy = year on year; Fx. adj. = currency-adjusted<br />
36.4% (Fx adj. +9.0%)<br />
Emerging markets<br />
HEALTHCARE<br />
In the emerging markets, HealthCare raised sales by 10.1% (Fx adj.) in 2011 to €5,510�million<br />
(2010:�€5,110�million), recording its strongest gain in China. The 19.2% (Fx adj.) increase in China<br />
was achieved by stepping up our marketing activities, especially the expansion of our distribution<br />
network, in line with our growth strategy. Business in the Latin America region also developed well,<br />
with particularly good growth in Brazil, Mexico, Venezuela and Argentina, especially for our pharmaceutical<br />
products. Sales also gained signifi cantly in Russia. The emerging markets accounted for<br />
32.1% (2010:�30.2%) of total HealthCare sales.
Change language